Concurrent Gabapentin and Opioid Use and Risk of Mortality in Medicare Recipients with Non‐Cancer Pain
Clinical Pharmacology & Therapeutics · 2023-11 · 114 (5) · 1050-1057
DOI: 10.1002/cpt.3019 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 25.08.2023. Verfasst von Meghan A Corriere und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA. Hauptthemen laut MEDLINE: Gabapentin, Medicare, Analgesics, Opioid, Duloxetine Hydrochloride. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAMS NIH HHS.
Abstract (Originalsprache)
Gabapentin is prescribed for pain and is perceived as safe generally. However, gabapentin can cause respiratory depression, exacerbated by concomitant central nervous system depressants (e.g., opioids), a concern for vulnerable populations. We compared mortality rates among new users of either gabapentin or duloxetine with or without concurrent opioids in the 20% Medicare sample. We conducted a new‐user design retrospective cohort study, in Medicare enrollees ages 65–89 years with noncancer chronic pain and no severe illness who filled prescriptions between 2015 and 2018 for gabapentin ( n = 233,060) or duloxetine ( n = 34,009). Daily opioid doses, estimated in morphine milligram equivalents (MMEs), were classified into none, low (0 < MME < 50), and high (≥ 50 MME), based on Centers for Disease Control and Prevention (CDC) recommendations. The outcomes were all‐cause mortality (primary) and out‐of‐hospital mortality (secondary). We used inverse probability of treatment weighting to adjust for differences between gabapentin and duloxetine users. During 116,707 person‐years of follow‐up, 1,379 patients died. All‐cause mortality rate in gabapentin users was 12.16 per 1,000 person‐years vs. 9.94 per 1,000 in duloxetine users. Risks were similar for users with no concurrent opioids (adjusted hazard ratio (aHR) = 1.03, 95% confidence interval (CI): 0.80–1.31) or low‐dose daily opioids (aHR = 1.06, 95% CI: 0.63–1.76). However, gabapentin users receiving concurrent high‐dose daily opioids had an increased rate of all‐cause mortality compared with duloxetine users on high‐dose opioids (aHR = 2.03, 95% CI: 1.19–3.46). Out‐of‐hospital mortality yielded similar results. In this retrospective cohort study of Medicare beneficiaries, concurrent use of high‐dose opioids and gabapentin was associated with a higher all‐cause mortality risk than that for concurrent use of high‐dose opioids and duloxetine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
- Vertex Pharmaceuticals, Boston, Massachusetts, USA.
- Department of Medicine, University of Miami, Miami, Florida, USA.
- Department of Biostatistics, Vanderbilt University, Nashville, Tennessee, USA.
- Department of Health Policy, Vanderbilt University, Nashville, Tennessee, USA.
- Bruce W. Carter Department of Veterans Affairs Medical Center, Miami, Florida, USA.
ORCID-Profile: Meghan A Corriere, Laura L Daniel, Alyson L Dickson, Puran Nepal, William D Dupont, Katherine T Murray, Cecilia P Chung
Förderung
- NIAMS NIH HHS
Zitieren
APA
Corriere, M. A., Daniel, L. L., Dickson, A. L., Nepal, P., Hall, K., Plummer, W. D., Dupont, W. D., Murray, K. T., Stein, C. M., Ray, W. A., & Chung, C. P. (2023). Concurrent Gabapentin and Opioid Use and Risk of Mortality in Medicare Recipients with Non‐Cancer Pain. Clinical Pharmacology & Therapeutics, 114(5), 1050-1057. https://doi.org/10.1002/cpt.3019
Vancouver
Corriere MA, Daniel LL, Dickson AL, Nepal P, Hall K, Plummer WD, et al. Concurrent Gabapentin and Opioid Use and Risk of Mortality in Medicare Recipients with Non‐Cancer Pain. Clinical Pharmacology & Therapeutics. 2023;114(5):1050-1057. doi:10.1002/cpt.3019
BibTeX
@article{Corriere2023,
author = {Corriere, Meghan A and Daniel, Laura L and Dickson, Alyson L and Nepal, Puran and Hall, Kathi and Plummer, W Dale and Dupont, William D and Murray, Katherine T and Stein, C Michael and Ray, Wayne A and Chung, Cecilia P},
title = {Concurrent Gabapentin and Opioid Use and Risk of Mortality in Medicare Recipients with Non‐Cancer Pain},
journal = {Clinical Pharmacology & Therapeutics},
year = {2023},
volume = {114},
number = {5},
pages = {1050--1057},
doi = {10.1002/cpt.3019}
}
EUVIMED